Report of Foreign Issuer (6-k)
December 06 2016 - 10:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of December 2016
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.
EXHIBIT
LIST
Exhibit |
Title |
|
|
99.1 |
News Release Dated December 1, 2016 - Medicure Closes Acquisition of Majority Interest in Apicore |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Medicure Inc. |
|
(Registrant) |
|
|
|
|
|
Date: December 1, 2016 |
By: |
/s/ Dr. Albert D. Friesen |
|
Dr. Albert D. Friesen |
|
Title: President & CEO |
Exhibit 99.1
Medicure Closes Acquisition of Majority Interest in Apicore
WINNIPEG, Dec. 1, 2016 /CNW/ - Medicure Inc. ("Medicure"
or the "Company") (TSXV:MPH, OTC:MCUJF), a leading Canadian specialty pharmaceutical company, is pleased to announce
that it has closed its acquisition for a majority interest in Apicore Inc. and the interests of Apigen Investments Limited (together
"Apicore"), as previously announced on November 18, 2016. The acquisition consists of the purchase of 4,717,000
Series A Preferred Shares and 1,250,000 Warrants in Apicore for US$33,750,000. This brings Medicure's ownership in Apicore
to 64% (or approximately 60% on a fully diluted basis).
Medicure's initial ownership interest and option rights were
obtained for its lead role in structuring and participating in a majority interest purchase and financing of Apicore that occurred
on July 3, 2014. Medicure continues to have option rights until July 3, 2017 to acquire additional shares in Apicore.
About Apicore
Apicore is a private, New Jersey based developer and manufacturer
of specialty Active Pharmaceutical Ingredients ("APIs") and pharmaceuticals, including over 15 Abbreviated New Drug Applications
("ANDAs"), one of which, is partnered with Medicure. Apicore manufactures over 100 different API's, including over
35 for which Drug Master Files have been submitted to the FDA and 12 that are approved for commercial sale in the U.S. by customers
of Apicore. Apicore specializes in the manufacture of difficult to synthesize, high value and other niche API's for many
U.S. and international generic and branded pharmaceutical companies. Apicore has 2 FDA-approved facilities. In the U.S.,
the Somerset, New Jersey facility can produce a few grams up to 200 kg volumes and in India, the Vadodara, Gujarat facility can
produce a few kilograms up to 60 metric tons yearly. Both facilities are equipped with state-of-the-art analytical and research
capabilities. For more information, please visit Apicore online at www.apicore.com.
About Medicure
Medicure is a specialty pharmaceutical company focused on
the development and commercialization of therapeutics for the U.S. hospital market. The primary focus of the Company and its subsidiaries
is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation acute coronary syndrome in the United States,
where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit
www.medicure.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
SOURCE Medicure Inc.
%CIK: 0001133519
For further information: James Kinley, Chief Financial Officer,
Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com
CO: Medicure Inc.
CNW 10:22e 01-DEC-16
This regulatory filing also includes additional resources:
ex991.pdf
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Feb 2024 to Mar 2024
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Mar 2023 to Mar 2024